Brain metastases free survival differs between breast cancer subtypes (Q35739534)

10 August 2017

Brain metastases free survival differs between breast cancer subtypes (English)

1 reference

10 August 2017

A Berghoff

1

1 reference

10 August 2017

Z Bago-Horvath

2

1 reference

10 August 2017

C De Vries

3

1 reference

10 August 2017

P Dubsky

4

1 reference

10 August 2017

U Pluschnig

5

1 reference

10 August 2017

M Rudas

6

1 reference

10 August 2017

A Rottenfusser

7

1 reference

10 August 2017

M Knauer

8

1 reference

10 August 2017

H Eiter

9

1 reference

10 August 2017

F Fitzal

10

1 reference

10 August 2017

K Dieckmann

11

1 reference

10 August 2017

R M Mader

12

1 reference

10 August 2017

M Gnant

13

1 reference

10 August 2017

C C Zielinski

14

1 reference

10 August 2017

G G Steger

15

1 reference

10 August 2017

M Preusser

16

1 reference

10 August 2017

R Bartsch

17

1 reference

10 August 2017

language of work or name

English

0 references

publication date

10 January 2012

1 reference

British Journal of Cancer

10 August 2017

1 reference

10 August 2017

106

1 reference

10 August 2017

3

1 reference

10 August 2017

440-446

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.2011.597

10 August 2017

0 references

cites work

Factors influencing survival in patients with breast cancer and single or solitary brain metastasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3273356

The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3273356

How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3273356

Metastatic behavior of breast cancer subtypes

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3273356

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3273356

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3273356

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3273356

Brain metastases: the HER2 paradigm

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3273356

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3273356

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3273356

Second consensus on medical treatment of metastatic breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3273356

Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3273356

Breast cancer metastasis to the central nervous system

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3273356

Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3273356

Repeated observation of breast tumor subtypes in independent gene expression data sets

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3273356

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3273356

Molecular portraits of human breast tumours

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3273356

The prognostic analysis of clinical breast cancer subtypes among patients with liver metastases from breast cancer.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3273356

Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3273356

The effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival and cause of death.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3273356

Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3273356

Brain metastases and subtypes of breast cancer.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3273356

Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3273356

Identification of patients who may benefit from the prophylactic cranial radiotherapy among breast cancer patients with brain metastasis

25 September 2018

1 reference

12 December 2020

1 reference

12 December 2020

Meningeal carcinomatosis in breast cancer: prognostic factors and outcome

1 reference

12 December 2020

Risk factors for brain relapse in patients with metastatic breast cancer

1 reference

12 December 2020

Brain metastases in patients with advanced breast cancer

1 reference

12 December 2020

Occult brain metastases in HER2-positive breast cancer patients: frequency and response to radiotherapy

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.2011.597

1 reference

10 August 2017

1 reference

10 August 2017

1 reference